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Insulin secretion is thought principally to be
regulated by blood glucose concentration. Three
recent studies emphasise the additional importance
of fatty acids as regulators of insulin secretion, and
demonstrate the involvement of a novel G protein-
coupled receptor.
The tight regulation of normal blood glucose
concentrations is largely achieved by the minute-to-
minute regulation of insulin production by pancreatic
islet β-cells, and loss of β-cell mass or function
underlies the onset of both type 1 and type 2 diabetes
mellitus. This condition, whose prevalence in western
societies has risen alarmingly in recent years to affect
3–5% of the population, is increasingly seen as an
‘epidemic’ of the 21st century [1]. New therapeutic
strategies are thus eagerly sought.
Blood glucose concentration is the most important
regulator of insulin release, and the molecular
mechanisms involved in the secretory response are
increasingly well understood [2]. These rely on
intracellular metabolism of the sugar, the generation
of ATP, closure of ATP-sensitive K+ channels (KATP),
and Ca2+ influx [2] (Figure 1, blue box). KATP channel-
independent or ‘amplifying’ mechanisms may also be
involved [3].
Whilst other nutrients, including fatty acids, can
also trigger insulin release from pancreatic β-cells
[4,5], the mechanisms which mediate the effects of
these molecules are disputed. Fatty acids such as
palmitate can certainly be metabolised by isolated
islets [6] and slightly increase the intracellular
ATP/ADP ratio [5]. But the effects of fatty acids on
insulin secretion are most marked at high glucose
concentrations, where palmitate has little or no addi-
tional effect on the intracellular ATP/ADP ratio [5].
Moreover, 2-bromopalmitate, a non-metabolisable
inhibitor of fatty acid oxidation, activates insulin
secretion from clonal β-cells [7] and the effects of
palmitate are strongly potentiated at high glucose
concentrations, where fatty acid oxidation is inhibited
[8]. These findings argue against an important role for
enhanced oxidative metabolism in the secretagogue
effects of fatty acids.
It has been known for some years that saturated [5]
and unsaturated [9] fatty acids both increase intracel-
lular Ca2+ concentrations, in part by mobilizing intra-
cellular Ca2+ [9], and they are able to stimulate
secretion even when KATP channels are fully activated
[5,10]. These observations suggested that fatty acids
may directly open intracellular Ca2+ channels. The new
findings of Briscoe et al. [11], Itoh et al. [12] and of
Kotarsky et al. [13] now provide an alternative mecha-
nism, by implicating an ‘orphan’ — that is, with no
identified ligand — G protein-coupled, seven trans-
membrane-spanning receptor, termed GPR40. 
Using a ‘ligand fishing’ strategy, Briscoe et al. [11]
explored the effects of a library of >1500 potential
ligands on intracellular [Ca2+] in HEK 293 cells
overexpressing GPR40 [11]. Both saturated and
unsaturated fatty acids with chain length of more than
six activated the receptors, each with similar potency.
An essentially identical approach by Itoh et al. [12]
gave similar results, though they were also able to
demonstrate small differences in the relative poten-
cies of different fatty acids, with linoleic acid (C18:2)
having half-maximal effects at the lowest concentra-
tion (1.8 µM). This group also showed that the effec-
tive fatty acids had no effect on intracellular levels of
cyclic (c)AMP. Kotarsky et al. [13] report qualitatively
similar findings, and importantly also found that
rosiglitazone, a drug of the thiazolidinedione class
already used to treat insulin resistance in type 2
diabetes [14], mobilises Ca2+ in clonal β-cells. 
These results suggest that the most likely
mechanism for coupling of the receptor from a
number of species may be via G-proteins of the Gqα
class which regulate the activity of phospholipase Cβ
[15]. The generation of inositol 1,4,5 trisphosphate
(IP3) then presumably mobilizes Ca2+ from intracellu-
lar stores [16], thus enhancing insulin release [2]
(Figure 1, green box).
A remarkable aspect of the new results is that the
expression of GPR40 mRNA in rats was almost
exclusively confined to the pancreas, with very minor
expression in the upper intestine [12]. The latter finding
is also of interest as it may be linked to the ability of
free fatty acids to stimulate the release from the gut of
cholecystokinin, a potential satiety factor [17]. In
humans, GRP40 mRNA was strongly expressed in both
pancreas and brain [11,13]. Two observations suggest
that GPR40 expression is largely confined to islet β-
cells: first, GPR40 expression was increased in the
islets of genetically obese (ob/ob) compared to lean
(wild type) mice, in parallel with an increase in β-cell
number; and second, GPR40 mRNA was found to be
highly abundant in clonal β-cells [11–13], but absent
from pancreatic α-cells and exocrine pancreas-derived
cell lines.
Consistent with these findings, oleic (C18:1) and
linoleic (C18:2) acid markedly potentiated insulin
release from MIN6 β-cells at permissive glucose
concentrations (> 5.5 mM), but had no effect in the
complete absence of glucose [12]. Crucially, small
interfering (si)RNAs [18] expected selectively to
silence GPR40 expression strongly inhibited the ability
of fatty acids to stimulate insulin release.
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The new studies, though undoubtedly important, do
leave some unanswered questions. It is not yet clear,
for example, whether the small differences in the appar-
ent efficacy of saturated versus unsaturated fatty acids
to activate GPR40 will be reflected in vivo, and whether
they are related to the well-known health benefits of a
diet richer in the latter. Secondly, we do not yet know
whether GPR40 also plays a role in the triggering of
secretion by glucose. Such a prospect is tantalizing as
glucose-induced accumulation of malonyl-CoA, which
inhibits fatty acid oxidation [19], and the generation of
fatty acids such as arachidonate [10], have both been
described in β-cells and could conceivably act, at least
in part, by stimulating GPR40 (Figure 1). But it seems
unlikely that the release of fatty acids contributes to the
KATP-independent pathway of glucose-stimulated
insulin secretion [3], as this is observed even when
intracellular [Ca2+] is clamped [3]. Finally, whilst the
studies with siRNA on isolated clonal cells are informa-
tive [12], complete understanding of the role of these
receptors will require their inactivation both in intact
isolated islets and in the β-cells of live mice.
The new studies provide important insights into a
number of previously puzzling aspects of nutrient-
secretion coupling in islets. In particular, they may
explain why fatty acids, like other important G protein-
coupled agonists such as glucagon-like peptide-1 [20],
act as ‘potentiators’ rather than ‘initiators’ of insulin
secretion. Both agonists thus act only in the presence
of elevated glucose concentrations — clearly an impor-
tant safeguard during starvation where free fatty acid
levels can be elevated but insulin release is undesirable.
Agonists of GRP40, and possibly other, as-yet uniden-
tified G protein-coupled receptors, may thus provide
important new drug targets for the treatment of type 2
diabetes which avoid the risk of hypoglycaemia.
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Figure 1. Regulation of insulin secretion
by glucose and fatty acids.
Glucose metabolism leads to the closure
of KATP channels, cell depolarisation and
Ca2+ influx via L-type Ca2+ channels (L-
Ca; blue box). Binding of fatty acids to
GPR40 leads to GTP-loading of Gqα, acti-
vation of phospholipase Cβ (PLCβ) and
hydrolysis of phosphatidylinositol 4,5 bis-
phosphate (PIP2). This generates inositol
1,4,5 trisphosphate (IP3) and leads to the
mobilisation of intracellular Ca2+ from the
endoplasmic reticulum (ER; green box).
Increases in cytosolic Ca2+ concentration
then trigger the release of stored insulin.
FA, fatty acid.
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